Development of a Vertical Flow Dot-Immunobinding Assay (Dot-Iba) for Rapid Detection of Neoscytalidium dimidiatum
Mycopathologia · 2026-04 · 191 (2)
DOI: 10.1007/s11046-026-01066-5 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Mycopathologia, online erschienen am 10.03.2026. Verfasst von Akkarapong Plengpanich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. Hauptthemen laut MEDLINE: Antigens, Fungal, Ascomycota. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siriraj Research Development Fund of the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand, Mahidol University.
Abstract (Originalsprache)
Neoscytalidium dimidiatum is a non-dermatophyte mold that commonly causes skin and nail infections in tropical regions and often resists conventional antifungal therapies. Because its clinical and laboratory features often resemble dermatophyte infections, diagnosis is frequently delayed and treatment is sometimes inappropriate. We therefore developed a dot-immunobinding assay (Dot-Iba) to detect N. dimidiatum antigens. We generated a highly specific monoclonal antibody, 3E6F7 (MAb 3E6F7), for antigen capture, and used goat anti-mouse Ig conjugated with alkaline phosphatase (AP) as the signal generator. The test pad comprised a test hole, a nitrocellulose membrane (NC), and water-absorbent pads in a vertical flow-through format to allow a rapid antigen–antibody reaction. The assembled system detected N. dimidiatum antigens in vitro with high specificity and yielded visible results within 2 h; its detection limit was 0.9 µg without cross-reactivity to dermatophyte or non-dermatophyte fungi. This rapid, specific, and easy-to-use assay shows strong potential as a diagnostic tool, particularly in settings with limited access to fungal culture or advanced molecular diagnostics, where early, accurate identification is crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Siriraj Center of Research Excellence in Allergy & Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. pichet.rue@mahidol.edu.
Förderung
- Siriraj Research Development Fund of the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
- Mahidol University
Zitieren
APA
Plengpanich, A., Bunyaratavej, S., Tungtrongchitr, A., Saelim, N., Srisai, T., Leeyaphan, C., Chongtrakool, P., & Ruenchit, P. (2026). Development of a Vertical Flow Dot-Immunobinding Assay (Dot-Iba) for Rapid Detection of Neoscytalidium dimidiatum. Mycopathologia, 191(2). https://doi.org/10.1007/s11046-026-01066-5
Vancouver
Plengpanich A, Bunyaratavej S, Tungtrongchitr A, Saelim N, Srisai T, Leeyaphan C, et al. Development of a Vertical Flow Dot-Immunobinding Assay (Dot-Iba) for Rapid Detection of Neoscytalidium dimidiatum. Mycopathologia. 2026;191(2). doi:10.1007/s11046-026-01066-5
BibTeX
@article{Plengpanich2026,
author = {Plengpanich, Akkarapong and Bunyaratavej, Sumanas and Tungtrongchitr, Anchalee and Saelim, Nawannaporn and Srisai, Thapani and Leeyaphan, Charussri and Chongtrakool, Piriyaporn and Ruenchit, Pichet},
title = {Development of a Vertical Flow Dot-Immunobinding Assay (Dot-Iba) for Rapid Detection of Neoscytalidium dimidiatum},
journal = {Mycopathologia},
year = {2026},
volume = {191},
number = {2},
doi = {10.1007/s11046-026-01066-5}
}
EUVIMED